Our Pricing

How to Switch to Wegovy from Mounjaro: Complete UK Dose Conversion and Nausea Management Guide

Many patients considering how to switch to Wegovy from Mounjaro need clear guidance on dose conversion protocols and managing potential nausea during the transition. Both medications are GLP-1 receptor agonists approved for chronic weight management in the UK, but they contain different active ingredients requiring careful dose matching. This comprehensive guide, reviewed by our superintendent pharmacist Tarun Kumar (GPhC 2233073), provides evidence-based protocols for safely transitioning between these treatments whilst minimising gastrointestinal side effects.

Understanding the Switch to Wegovy from Mounjaro: Key Differences

When you switch to Wegovy from Mounjaro, you're transitioning from tirzepatide (a dual GIP/GLP-1 receptor agonist) to semaglutide (a selective GLP-1 receptor agonist). Whilst both medications work through GLP-1 pathways to reduce appetite and slow gastric emptying, Mounjaro's additional GIP activity may contribute to different tolerability profiles between the two treatments [1].

Clinical trials demonstrate that both medications achieve significant weight reduction, with the STEP programme showing semaglutide (Wegovy) produced average weight loss of 15-17% over 68 weeks, whilst the SURPASS trials showed tirzepatide (Mounjaro) achieved 15-22% weight reduction depending on dose [2]. The decision to switch to Wegovy from Mounjaro often relates to cost considerations, availability, or individual tolerability rather than efficacy differences.

From a practical standpoint, Wegovy offers a simpler dosing schedule with weekly injections up to a maximum of 2.4mg, compared to Mounjaro's range extending to 15mg weekly. At Cured Pharmacy, Wegovy is available from £124.99 subject to clinical assessment, making it a cost-effective alternative for many patients currently prescribed Mounjaro.

Dose Conversion Chart: Switch to Wegovy from Mounjaro Safely

There is no officially sanctioned direct dose equivalence when you switch to Wegovy from Mounjaro, as the medications have different mechanisms and potencies. However, UK prescribers typically follow conservative conversion protocols based on clinical experience and the relative efficacy data from respective trial programmes [3].

The general approach when switching to Wegovy from Mounjaro involves restarting Wegovy at a lower therapeutic dose rather than attempting exact milligram-for-milligram conversion. Most clinicians recommend beginning Wegovy at either the 0.5mg or 1mg dose depending on your current Mounjaro dose and tolerability, then titrating upward according to the standard Wegovy escalation schedule.

Recommended Conversion Protocol for Switch to Wegovy from Mounjaro

If you're currently on Mounjaro 2.5mg or 5mg, your prescriber will likely initiate Wegovy at 0.25mg weekly for four weeks, then increase to 0.5mg as per the standard titration schedule. For patients on Mounjaro 7.5mg to 12.5mg, starting Wegovy at 0.5mg or 1mg may be appropriate, bypassing the initial 0.25mg dose. Those on Mounjaro 15mg typically begin Wegovy at 1mg weekly, progressing toward the maximum 2.4mg dose over subsequent months [4].

The transition period between stopping Mounjaro and starting Wegovy should be minimal—typically beginning Wegovy the week after your last Mounjaro injection maintains therapeutic continuity whilst allowing the previous medication to clear. This approach, recommended by most UK weight management services, helps sustain appetite suppression and minimises rebound hunger during the switch to Wegovy from Mounjaro.

Managing Nausea When You Switch to Wegovy from Mounjaro

Nausea represents the most commonly reported side effect during the switch to Wegovy from Mounjaro, affecting approximately 20-44% of patients in clinical trials, particularly during dose escalation phases [5]. Interestingly, some patients transitioning from Mounjaro may experience less nausea with Wegovy if they previously struggled with tirzepatide's dual-agonist effects, whilst others may find semaglutide produces more pronounced gastrointestinal symptoms.

The severity and duration of nausea when you switch to Wegovy from Mounjaro typically correlates with the starting dose selected and how rapidly titration occurs. Following a conservative escalation schedule—spending at least four weeks at each dose level—significantly reduces the incidence and intensity of nausea compared to accelerated protocols.

Evidence-Based Strategies to Reduce Nausea During the Switch to Wegovy from Mounjaro

Dietary modifications prove remarkably effective in managing nausea when you switch to Wegovy from Mounjaro. Consuming smaller, more frequent meals throughout the day rather than three large meals reduces gastric distension and works synergistically with Wegovy's gastric-emptying effects. Avoiding high-fat, spicy, or heavily processed foods for the first 48 hours following each injection minimises triggering nausea, as these foods require longer gastric processing time.

Timing your Wegovy injection strategically can also influence nausea severity during the switch to Wegovy from Mounjaro. Many patients report better tolerability when administering injections in the evening before bed, allowing peak nausea periods to occur during sleep. Staying well-hydrated with small, frequent sips of water or ginger tea throughout the day supports gastric comfort, though avoiding large fluid volumes immediately before or after meals prevents excessive stomach distension [6].

If nausea persists despite these measures when you switch to Wegovy from Mounjaro, consult your prescriber about temporarily reducing your dose or extending the time spent at your current dose level before escalating further. In some cases, anti-emetic medications such as domperidone or prochlorperazine may be prescribed short-term to manage severe symptoms, though these should only be used under medical supervision.

Clinical Considerations for the Switch to Wegovy from Mounjaro

Before you switch to Wegovy from Mounjaro, your prescriber will review your treatment history, current dose, weight loss achieved, and any side effects experienced on tirzepatide. This assessment ensures Wegovy represents an appropriate alternative and identifies any contraindications specific to semaglutide, such as personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Blood glucose monitoring becomes particularly important for patients with type 2 diabetes who switch to Wegovy from Mounjaro, as the change in medication potency and mechanism may affect glycaemic control. Whilst both medications improve insulin sensitivity and reduce HbA1c, the transition period requires vigilance to prevent hypoglycaemia, especially in patients taking concurrent diabetes medications [7].

At Cured Pharmacy, all patients requesting to switch to Wegovy from Mounjaro undergo a comprehensive clinical assessment by our UK-registered prescribers. This ensures continuity of care, appropriate dose selection, and ongoing monitoring throughout the transition period. Wegovy is available from £124.99 subject to prescriber approval, with transparent pricing displayed before your consultation begins.

Cost Comparison: Financial Benefits of the Switch to Wegovy from Mounjaro

One of the primary drivers for patients choosing to switch to Wegovy from Mounjaro relates to cost differences between these treatments in the UK private market. Wegovy typically costs significantly less than Mounjaro at equivalent therapeutic doses, making it an economically attractive option for long-term weight management.

At Cured Pharmacy, Wegovy is available from £124.99 compared to Mounjaro from £124.99, representing substantial monthly savings when you switch to Wegovy from Mounjaro. Over a typical 12-month treatment course, this price difference can amount to hundreds of pounds in savings whilst maintaining comparable clinical efficacy for weight reduction.

Additionally, new patients switching to Wegovy from Mounjaro can access £20 off their first order using code Weightlossnew, further reducing initial treatment costs. Our transparent pricing model ensures you know the exact cost before completing your clinical assessment, with no hidden fees or unexpected charges.

Long-Term Value When You Switch to Wegovy from Mounjaro

Beyond immediate cost savings, the switch to Wegovy from Mounjaro may offer improved long-term value through established supply chains and broader availability across UK pharmacies. Wegovy's longer market presence in the UK weight management sector has resulted in more stable supply compared to periodic Mounjaro shortages experienced throughout 2023-2024.

For patients planning extended treatment duration—often 12-24 months or longer for sustained weight management—the cumulative savings when you switch to Wegovy from Mounjaro become increasingly significant. These financial benefits support treatment adherence and reduce the likelihood of discontinuation due to cost pressures, ultimately improving long-term weight loss outcomes [8].

What to Expect After You Switch to Wegovy from Mounjaro

Most patients who switch to Wegovy from Mounjaro maintain their weight loss trajectory without significant disruption, provided appropriate dose conversion protocols are followed. During the first 4-8 weeks following the switch to Wegovy from Mounjaro, you may notice subtle differences in appetite suppression patterns, injection site reactions, or gastrointestinal symptoms as your body adapts to semaglutide.

Appetite control typically remains consistent when you switch to Wegovy from Mounjaro, though some patients report the subjective 'feel' of satiety differs slightly between the medications. These differences rarely impact overall efficacy, with most patients continuing to lose weight or maintain their achieved weight loss throughout the transition period and beyond.

Regular follow-up with your prescriber during the first three months after you switch to Wegovy from Mounjaro ensures optimal dose titration and allows prompt management of any emerging side effects. At Cured Pharmacy, our clinical team remains available for ongoing support throughout your treatment journey, with straightforward access to prescription renewals and dose adjustments as needed.

Scientific References

1. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
2. Wilding, J. P., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
4. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
5. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 15 August 2026]
6. Blundell, J., Finlayson, G., Axelsen, M., et al. (2017). Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism, 19(9), 1242-1251. [accessed 15 August 2026]
7. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet, 397(10278), 971-984. [accessed 15 August 2026]
8. Wadden, T. A., Bailey, T. S., Billings, L. K., et al. (2021). Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA, 325(14), 1403-1413. [accessed 15 August 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.